Metraipolis › archive › dc_80fefd07e77b

Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world… — Europe PMC PMID:42774967

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42774967
DOI
10.1016/j.gore.2026.102198
License (as archived)
solo-consultazione
Archived
2026-10-15T16:03:59.380Z
SHA-256 of the archived text
4308c08078dc72aa9b1cda7bee835e72b734cb73c707038259429148dd736933
Stable URL of this page
https://metraipolis.com/documento/dc_80fefd07e77b

How to cite

Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world… — Europe PMC PMID:42774967 — Europe PMC (en), https://europepmc.org/article/MED/42774967 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_80fefd07e77b (Metraipolis archive dc_80fefd07e77b, sha256 4308c08078dc72aa9b1cda7bee835e72b734cb73c707038259429148dd736933)
BibTeX
@misc{dc80fefd07e77b,
  title = {Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world… — Europe PMC PMID:42774967},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42774967},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_80fefd07e77b; sha256 4308c08078dc72aa9b1cda7bee835e72b734cb73c707038259429148dd736933},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42774967. Agents can read the archived copy with the MCP tool read_document.